Video

Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting

Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.

Video Player is loading.
Current Time 0:00
Duration 1:37
Loaded: 10.06%
Stream Type LIVE
Remaining Time 1:37
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Arjun V. Balar, MD, discusses the use of the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of metastatic renal cell carcinoma. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.

    © 2025 MJH Life Sciences

    All rights reserved.